efavirenz has been researched along with Cognition Disorders in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arends, JE; Ensing, MHM; Hakkers, CS; Hoepelman, AIM; Hooijenga, I; van den Berk, GE; van Zandvoort, MJE; Vink, M | 1 |
| Adamson, L; Blake, KH; Eron, JJ; Forrest, A; Joseph, SB; Kashuba, ADM; Kincer, LP; Luciw, P; Menezes, P; Price, RW; Robertson, K; Schauer, AP; Spudich, S; Srinivas, N; Swanstrom, R; Sykes, C; White, N | 1 |
| Decloedt, EH; Maartens, G | 1 |
| Brown, LA; Ferrell, D; Giunta, B; Jin, J; Obregon, D; Sadic, E; Smith, AJ; Tan, J | 1 |
| Alonso-Villaverde, C; Ferrer, E; Martinez-Picado, J; Maso, M; Muñoz-Moreno, JA; Ouchi, D; Podzamczer, D; Prats, A; Puertas, MC; Rozas, N; Tiraboschi, JM | 1 |
| Baldonero, E; Bracciale, L; Cauda, R; Ciccarelli, N; De Luca, A; Di Giambenedetto, S; Fabbiani, M; Fanti, I; Silveri, MC; Tamburrini, E | 1 |
| Cooper, DA; Duncombe, C; Emery, S; Gill, JM; Kerr, SJ; Li, PC; Puls, R; Taylor-Robinson, SD; Winston, A | 1 |
| Delmas, B; Lochet, P; Lotthé, A; Mauboussin, JM; Peyrière, H; Reynes, J | 1 |
| Cruttenden, K; DiCenzo, R; Gelbard, H; Morse, G; Peterson, D; Riggs, G; Schifitto, G | 1 |
| Burger, D; Clotet, B; Ferrer, MJ; Fumaz, CR; Gómez, G; Moltó, J; Muñoz-Moreno, JA; Negredo, E; Pérez-Alvarez, N; Sirera, G | 1 |
1 review(s) available for efavirenz and Cognition Disorders
| Article | Year |
|---|---|
Neuronal toxicity of efavirenz: a systematic review.
Topics: Alkynes; Animals; Benzoxazines; Brain; Calcium; Cognition Disorders; Cyclopropanes; Drug Tolerance; Humans; Neurons; Neurotoxicity Syndromes; Reverse Transcriptase Inhibitors | 2013 |
3 trial(s) available for efavirenz and Cognition Disorders
| Article | Year |
|---|---|
Objective and Subjective Improvement of Cognition After Discontinuing Efavirenz in Asymptomatic Patients: A Randomized Controlled Trial.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cognition Disorders; Cyclopropanes; Drug Substitution; HIV Infections; Humans; Male; Middle Aged; RNA, Viral; Treatment Outcome; Viral Load | 2019 |
Predicting Efavirenz Concentrations in the Brain Tissue of HIV-Infected Individuals and Exploring their Relationship to Neurocognitive Impairment.
Topics: Adult; Alkynes; Animals; Benzoxazines; Brain; Cognition Disorders; Cyclopropanes; Female; HIV Infections; Humans; Macaca mulatta; Male; Middle Aged; Young Adult | 2019 |
Dynamics of cognitive change in HIV-infected individuals commencing three different initial antiretroviral regimens: a randomized, controlled study.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cognition; Cognition Disorders; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Zidovudine | 2012 |
6 other study(ies) available for efavirenz and Cognition Disorders
| Article | Year |
|---|---|
Efavirenz promotes β-secretase expression and increased Aβ1-40,42 via oxidative stress and reduced microglial phagocytosis: implications for HIV associated neurocognitive disorders (HAND).
Topics: Alkynes; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Benzoxazines; Cell Line; Cognition Disorders; Cyclopropanes; Female; HIV Infections; Humans; Lamivudine; Mice; Oxidative Stress; Phagocytosis; Reverse Transcriptase Inhibitors; Zidovudine | 2014 |
Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during antiretroviral treatment switch.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Biomarkers; Cognition Disorders; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Drug Substitution; Emtricitabine; Enzyme-Linked Immunosorbent Assay; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Pilot Projects; Prospective Studies; Tenofovir; Tumor Necrosis Factor-alpha; Viral Load | 2015 |
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients.
Topics: Activities of Daily Living; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Case-Control Studies; Chi-Square Distribution; Cognition Disorders; Cohort Studies; Cyclopropanes; Female; HIV Infections; Humans; Male; Mental Status Schedule; Middle Aged; Neuropsychological Tests; Retrospective Studies; Young Adult | 2011 |
Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Anxiety Disorders; Benzoxazines; Cognition Disorders; Cyclopropanes; Depressive Disorder; Female; Follow-Up Studies; HIV Infections; Humans; Male; Mental Disorders; Middle Aged; Mood Disorders; Oxazines; Quality of Life; Sleep Wake Disorders; Surveys and Questionnaires | 2003 |
Effects of valproic acid coadministration on plasma efavirenz and lopinavir concentrations in human immunodeficiency virus-infected adults.
Topics: Adult; Alkynes; Anti-HIV Agents; Anticonvulsants; Area Under Curve; Benzoxazines; Cognition Disorders; Cyclopropanes; Drug Interactions; Female; Half-Life; HIV Infections; Humans; Lopinavir; Male; Oxazines; Pyrimidinones; Reverse Transcriptase Inhibitors; Valproic Acid | 2004 |
Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence.
Topics: Acquired Immunodeficiency Syndrome; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System Diseases; Cognition Disorders; Cyclopropanes; Employment; Female; Humans; Male; Mood Disorders; Oxazines; Patient Compliance; Quality of Life; Retrospective Studies; Risk-Taking; Surveys and Questionnaires | 2005 |